Scientists at The Scripps Institute (California, USA) have used liquid chromatography?mass spectrometry (LC?MS) to identify a new biomarker for the diagnosis of river blindness.1
Scientists at The Scripps Institute (California, USA) have used liquid chromatography–mass spectrometry (LC–MS) to identify a new biomarker for the diagnosis of river blindness.1 The discovery is an important step towards the development of a portable diagnostic test for use in the field.
River blindness affects 37 million people worldwide and is focused specifically in sub-Saharan Africa, Central and South America and Yemen. The disease is caused by nematode (Onchocerca volvulus) larvae transmitted by blackfly (Simulium sp.). In an attempt to kill the larvae, the body mounts an inflammatory immune response, indirectly damaging the eye and other body tissues.
The team analysed the urinary metabolome of infected and uninfected patients, identifying one particular protein that became elevated in the urine of infected patients. High performance liquid chromatography (HPLC) was performed to concentrate the protein and LC–MS was able to identify the chemical structure as N-acetyltyramine-O,ß-glucoronide.
The analysis was not as straightforward as initially hoped. The small, then unknown, molecule was not immediately identifiable. Daniel Globisch, a postdoctoral fellow in the Janda laboratory, studied the available literature referencing the metabolome of the nematode and pinpointed the metabolite source. The molecule was a breakdown product of a neurotransmitter produced by young larvae, excreted into the urine at higher levels during an active infection.
“It’s a spectacular find in terms of biomarkers as it does not occur naturally in humans,” said Globisch. Lead investigator Professor Janda advanced on this stating that for the findings to be of value in Third World countries it would need to be developed into a portable instrument, “basically distilling our finding to a test that can be carted around in a backpack”.
According to the authors, the theory behind the investigation should be applicable to the diagnosis of other worm infection-induced diseases.
Reference
1. D. Globisch, A. Moreno, M.S Hixon, A.A.K. Nunes, J.R. Denery,S. Specht, A. Hoerauf and K.D. Janda, PNAS, DOI: 10.1073/pnas.1221969110 (2013).
This story originally appeared in The Column. Click here to view that issue.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.